Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 8
1976 26
1977 14
1978 30
1979 43
1980 43
1981 62
1982 86
1983 71
1984 64
1985 73
1986 80
1987 77
1988 88
1989 70
1990 74
1991 48
1992 43
1993 54
1994 61
1995 51
1996 39
1997 39
1998 35
1999 48
2000 39
2001 38
2002 41
2003 41
2004 34
2005 53
2006 50
2007 61
2008 40
2009 31
2010 23
2011 32
2012 28
2013 36
2014 34
2015 32
2016 31
2017 20
2018 21
2019 22
2020 12
2021 14
2022 10
2023 1

Text availability

Article attribute

Article type

Publication date

Search Results

1,997 results

Results by year

Filters applied: . Clear all
Page 1
Metoprolol for the Prevention of Acute Exacerbations of COPD.
Dransfield MT, Voelker H, Bhatt SP, Brenner K, Casaburi R, Come CE, Cooper JAD, Criner GJ, Curtis JL, Han MK, Hatipoğlu U, Helgeson ES, Jain VV, Kalhan R, Kaminsky D, Kaner R, Kunisaki KM, Lambert AA, Lammi MR, Lindberg S, Make BJ, Martinez FJ, McEvoy C, Panos RJ, Reed RM, Scanlon PD, Sciurba FC, Smith A, Sriram PS, Stringer WW, Weingarten JA, Wells JM, Westfall E, Lazarus SC, Connett JE; BLOCK COPD Trial Group. Dransfield MT, et al. N Engl J Med. 2019 Dec 12;381(24):2304-2314. doi: 10.1056/NEJMoa1908142. Epub 2019 Oct 20. N Engl J Med. 2019. PMID: 31633896 Free PMC article. Clinical Trial.
There was no significant between-group difference in the median time until the first exacerbation, which was 202 days in the metoprolol group and 222 days in the placebo group (hazard ratio for metoprolol vs. placebo, 1.05; 95% confidence interval [CI], 0.84 to 1.32 …
There was no significant between-group difference in the median time until the first exacerbation, which was 202 days in the metoprolol …
Randomized Trial of Metoprolol in Patients With Obstructive Hypertrophic Cardiomyopathy.
Dybro AM, Rasmussen TB, Nielsen RR, Andersen MJ, Jensen MK, Poulsen SH. Dybro AM, et al. J Am Coll Cardiol. 2021 Dec 21;78(25):2505-2517. doi: 10.1016/j.jacc.2021.07.065. J Am Coll Cardiol. 2021. PMID: 34915981 Free article. Clinical Trial.

During metoprolol treatment, 14% of patients were in NYHA functional class III or higher compared with 38% of patients receiving placebo (P < 0.01). Similarly, no patients were in CCS class III or higher during metoprolol treatment compared with 10% during placeb

…
During metoprolol treatment, 14% of patients were in NYHA functional class III or higher compared with 38% of patients receiving plac …
Effects of Metoprolol on Exercise Hemodynamics in Patients With Obstructive Hypertrophic Cardiomyopathy.
Dybro AM, Rasmussen TB, Nielsen RR, Ladefoged BT, Andersen MJ, Jensen MK, Poulsen SH. Dybro AM, et al. J Am Coll Cardiol. 2022 Apr 26;79(16):1565-1575. doi: 10.1016/j.jacc.2022.02.024. J Am Coll Cardiol. 2022. PMID: 35450573 Free article. Clinical Trial.
CONCLUSIONS: In patients with obstructive HCM, exercise was associated with an abnormal rise in PCWP, which was unaffected by metoprolol. However, metoprolol increased SV at rest and peak exercise following changes in end-diastolic volume, LVOT gradient, and degree …
CONCLUSIONS: In patients with obstructive HCM, exercise was associated with an abnormal rise in PCWP, which was unaffected by metoprolol …
Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial.
POISE Study Group; Devereaux PJ, Yang H, Yusuf S, Guyatt G, Leslie K, Villar JC, Xavier D, Chrolavicius S, Greenspan L, Pogue J, Pais P, Liu L, Xu S, Málaga G, Avezum A, Chan M, Montori VM, Jacka M, Choi P. POISE Study Group, et al. Lancet. 2008 May 31;371(9627):1839-47. doi: 10.1016/S0140-6736(08)60601-7. Epub 2008 May 12. Lancet. 2008. PMID: 18479744 Free article. Clinical Trial.
More patients in the metoprolol group than in the placebo group had a stroke (41 [1.0%] vs 19 [0.5%] patients; 2.17, 1.26-3.74; p=0.0053). ...Patients are unlikely to accept the risks associated with perioperative extended-release metoprolol....
More patients in the metoprolol group than in the placebo group had a stroke (41 [1.0%] vs 19 [0.5%] patients; 2.17, 1.26-3.74; p=0.0 …
Metoprolol in acute myocardial infarction. Other clinical findings and tolerability. The MIAMI Trial Research Group.
[No authors listed] [No authors listed] Am J Cardiol. 1985 Nov 22;56(14):39G-46G. Am J Cardiol. 1985. PMID: 3904393 Clinical Trial.
Left ventricular failure was observed no more often in the metoprolol group. The occurrence of cardiogenic shock also did not differ between the groups. ...Atropine (4.1 vs 6.4%) and sympathomimetic (3.2 vs 4.6%) agents were used more often in the metoprolol group d …
Left ventricular failure was observed no more often in the metoprolol group. The occurrence of cardiogenic shock also did not differ …
MERIT-HF--description of the trial.
Wikstrand J. Wikstrand J. Basic Res Cardiol. 2000;95 Suppl 1:I90-7. doi: 10.1007/s003950070016. Basic Res Cardiol. 2000. PMID: 11192361 Review.
It was recommended to double the dose after each 2-week period in order to reach the highest tolerated dose aiming for a target dose level of 200 mg once daily of metoprolol CR/Zok or placebo. This dosage regimen could be modified according to the judgement of the investig …
It was recommended to double the dose after each 2-week period in order to reach the highest tolerated dose aiming for a target dose level o …
Efficacy and safety of extended release metoprolol succinate in hypertensive children 6 to 16 years of age: a clinical trial experience.
Batisky DL, Sorof JM, Sugg J, Llewellyn M, Klibaner M, Hainer JW, Portman RJ, Falkner B; Toprol-XL Pediatric Hypertension Investigators. Batisky DL, et al. J Pediatr. 2007 Feb;150(2):134-9, 139.e1. doi: 10.1016/j.jpeds.2006.09.034. J Pediatr. 2007. PMID: 17236889 Clinical Trial.
OBJECTIVE: To evaluate the efficacy, tolerability, and blood pressure (BP) lowering effect of extended release metoprolol succinate (ER metoprolol) in children 6 to 16 years of age with established hypertension. STUDY DESIGN: Patients were randomized to one of four …
OBJECTIVE: To evaluate the efficacy, tolerability, and blood pressure (BP) lowering effect of extended release metoprolol succinate ( …
Dose of metoprolol CR/XL and clinical outcomes in patients with heart failure: analysis of the experience in metoprolol CR/XL randomized intervention trial in chronic heart failure (MERIT-HF).
Wikstrand J, Hjalmarson A, Waagstein F, Fagerberg B, Goldstein S, Kjekshus J, Wedel H; MERIT-HF Study Group. Wikstrand J, et al. J Am Coll Cardiol. 2002 Aug 7;40(3):491-8. doi: 10.1016/s0735-1097(02)01970-8. J Am Coll Cardiol. 2002. PMID: 12142116 Free article. Clinical Trial.
OBJECTIVES: We performed a post-hoc subgroup analysis in the Metoprolol CR/XL Randomized Intervention Trial in Chronic Heart Failure (MERIT-HF) with the aim of reporting on the heart rate (HR) response during the titration phase and clinical outcomes from the three-month f …
OBJECTIVES: We performed a post-hoc subgroup analysis in the Metoprolol CR/XL Randomized Intervention Trial in Chronic Heart Failure …
Drug disposition and modelling before and after gastric bypass: immediate and controlled-release metoprolol formulations.
Gesquiere I, Darwich AS, Van der Schueren B, de Hoon J, Lannoo M, Matthys C, Rostami A, Foulon V, Augustijns P. Gesquiere I, et al. Br J Clin Pharmacol. 2015 Nov;80(5):1021-30. doi: 10.1111/bcp.12666. Epub 2015 Jul 6. Br J Clin Pharmacol. 2015. PMID: 25917170 Free PMC article. Clinical Trial.
METHODS: A single-dose pharmacokinetic study of metoprolol tartrate 200 mg immediate release and controlled release was performed in 14 volunteers before and 6-8 months after RYGB. The observed data were compared with predicted results from the PBPK modelling and simulatio …
METHODS: A single-dose pharmacokinetic study of metoprolol tartrate 200 mg immediate release and controlled release was performed in …
Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial.
Chen ZM, Pan HC, Chen YP, Peto R, Collins R, Jiang LX, Xie JX, Liu LS; COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group. Chen ZM, et al. Lancet. 2005 Nov 5;366(9497):1622-32. doi: 10.1016/S0140-6736(05)67661-1. Lancet. 2005. PMID: 16271643 Clinical Trial.
FINDINGS: Neither of the co-primary outcomes was significantly reduced by allocation to metoprolol. For death, reinfarction, or cardiac arrest, 2166 (9.4%) patients allocated metoprolol had at least one such event compared with 2261 (9.9%) allocated placebo (odds ra …
FINDINGS: Neither of the co-primary outcomes was significantly reduced by allocation to metoprolol. For death, reinfarction, or cardi …
1,997 results